Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant only for patients classified as highly…
Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) use was significantly associated with a reduced odds of five-year mortality, but this protective effect was found to be statistically significant only for patients classified as highly…